NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
26 Fevereiro 2024 - 10:00AM
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or
the “Company”), a late-stage, clinical biopharmaceutical company
developing oral, non-statin medicines for patients at risk of
cardiovascular disease with elevated low-density lipoprotein
cholesterol (“LDL-C”), for whom existing therapies are not
sufficiently effective or well-tolerated, today announced that
company management will participate in three upcoming investor
conferences:
- TD Cowen 44th Annual Health Care Conference in
Boston, MA on Monday, March 4, 2024. Michael Davidson, Chief
Executive Officer, and Ian Somaiya, Chief Financial Officer, will
present a corporate overview at 2:10 p.m. ET.
- Leerink Global Biopharma Conference in Miami,
FL on Monday, March 11, 2024. Michael Davidson, M.D., Chief
Executive Officer, will present a corporate overview at 4:00 p.m.
ET.
- Jefferies Biotech on the Bay Summit in Miami,
FL on Tuesday, March 12, 2024. Company management will be available
for 1x1 meetings throughout the day.
Live webcasts of both the Cowen and Leerink presentations will
be available through the investor relations section of the
NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following
the live webcast, an archived replay will be available on the
Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage
biopharmaceutical company whose mission is to improve patient care
in populations with metabolic diseases where currently approved
therapies have not been adequate or well tolerated. We seek to fill
a significant unmet need for a safe, well tolerated and convenient
LDL-lowering therapy. In multiple phase 3 studies, NewAmsterdam is
investigating obicetrapib, an oral, low-dose and once-daily CETP
inhibitor, alone or as a fixed-dose combination with ezetimibe, as
preferred LDL-C lowering therapies to be used as an adjunct to
statin therapy for patients at risk of CVD with elevated LDL-C, for
whom existing therapies are not sufficiently effective or well
tolerated.
Company ContactMatthew PhilippeP:
1-917-882-7512matthew.philippe@newamsterdampharma.com
Media ContactSpectrum Science on behalf of
NewAmsterdamJen GordonP:
1-202-957-7795jgordon@spectrumscience.com
Investor ContactStern Investor Relations on
behalf of NewAmsterdamHannah DeresiewiczP:
1-212-362-1200hannah.deresiewicz@sternir.com
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
NewAmsterdam Pharma Comp... (NASDAQ:NAMS)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024